Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-08-09 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Forxiga approved in the EU for CKD
Earnings Release Classification · 99% confidence The document begins with 'RNS Number' and is dated August 9, 2021. It announces a significant regulatory/marketing event: the approval of the drug Forxiga in the EU for treating chronic kidney disease. This type of announcement, which details a specific corporate event (a regulatory approval) and is distributed via the RNS system (London Stock Exchange's news service), fits best under the general 'Regulatory Filings' category, as it is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). While it is a press release, RNS serves as the primary distribution channel for such non-standardized regulatory news that doesn't fit the other specific codes. Given the context of a major drug approval announcement distributed via RNS, 'RNS' is the most appropriate classification. Q3 2021
2021-08-09 English
Enhertu head-to-head trial meets primary endpoint
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the RNS service of the London Stock Exchange. The content details positive clinical trial results (DESTINY-Breast03) for the drug Enhertu, including efficacy endpoints (PFS) and safety profiles, and mentions plans for global regulatory submissions. This type of announcement, which communicates material, non-public information to the market promptly, fits the description of a general regulatory filing or announcement that doesn't fit a more specific category like an Earnings Release (ER) or a full Annual Report (10-K). Since it is a formal announcement distributed through the official regulatory news service (RNS), the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (13,257 chars), but its primary function is the announcement itself, not the underlying detailed report.
2021-08-09 English
TOTAL VOTING RIGHTS
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date (31 July 2021), providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a regulatory disclosure about voting rights rather than a full report or financial statement. The document length is 3129 characters, which is relatively short and primarily serves as a notification of voting rights rather than a detailed report. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or status of significant share ownership or voting rights. It is not an announcement of a report publication, nor a full annual or interim report, nor a certification or legal proceeding. Therefore, the best classification is MRQ with high confidence.
2021-08-02 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing information under the 'UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1'. The content details the total number of issued shares with voting rights as of a specific date (31 July 2021) and serves as the denominator for shareholder notification calculations. This type of mandatory regulatory disclosure regarding capital structure and voting rights, distributed via the RNS service, fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Voting Rights Capital Update' outside of DVA (which is for voting *results*). Since it is a direct regulatory update distributed via RNS, RNS is the most appropriate classification.
2021-08-02 English
SAPHNELO APPROVED IN THE US FOR SLE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA approval of Saphnelo for systemic lupus erythematosus (SLE), including clinical trial data, drug description, and company background. The document is approximately 14,576 characters long, indicating it is a substantive report rather than a brief announcement. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document does not contain financial statements or quarterly results, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, proxy statement, or governance information. It is a regulatory filing reporting material news about product approval and clinical data. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-02 English
Saphnelo approved in the US for SLE
Regulatory Filings Classification · 100% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange. The content announces a specific regulatory event: the US FDA approval of a drug (Saphnelo) for systemic lupus erythematosus. This type of announcement, which is a material event disclosure to the market via an official news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a comprehensive financial report (10-K, IR), a management discussion (MDA), or a specific shareholder vote/dividend notice. Since it is a direct, time-sensitive regulatory announcement disseminated through RNS, the most appropriate code is RNS.
2021-08-02 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.